

Since this is a very extensive table, the format and content has not been edited by ActaDV.

Table SI. Detailed data of the patients

Timepoint	Patient	IGA	EASI	DLQI	POEM	TARC (pg/mL)	IgE (IU/mL)	Age (years)	Sex	BMI	Age of AD onset	Duration of first DUP treatment course (weeks)	Duration between discontinuation and re-initiation (weeks)
Exacerbation group													
0w	1	4	42	20	21	2431	5830	35	M	19.8	early childhood	43	13
16w		2	4.4	3	5	525	2980						
DUP dosing discontinuation		2	3.4	0	3	322	1570						
4w after DUP dosing discontinuation		2	3.6	1	2	322	1570						
8w after DUP dosing discontinuation		2	5.6	3	5	725	1400						
Initiation of DUP re-treatment		3	19.2	3	5	1073	1440						
16w after DUP re-initiation		2	4.5	1	2	683	1200						
0w	2	3	16.1	6	14	744	1930	50	F	no data	12y	38	9
16w		2	7.6	1	1	172	810						
DUP dosing discontinuation		1	0.8	0	0	172	810						
4w after DUP dosing discontinuation		1	0.8	0	0	172	810						
8w after DUP dosing discontinuation		1	0.8	0	0	172	810						
Initiation of DUP re-treatment		1	2	2	8	165	305						
16w after DUP re-initiation		0	0.8	0	0	165	305						
0w	3	4	42.9	15	26	1459	1000	51	M	26.6	10y	37	11
16w		2	18.5	6	15	587	383						
DUP dosing discontinuation		2	9	2	10	617	199						
4w after DUP dosing discontinuation		2	9	2	10	617	199						
8w after DUP dosing discontinuation		2	9	2	10	617	199						
Initiation of DUP re-treatment		3	17.2	7	19	1581	278						
16w after DUP re-initiation		3	9.9	3	9	1581	278						

0w	4	4	28.5	8	9	13360	9300	50	M	23.5	10y	45	12
16w		2	8.2	2	0	186	4370						
DUP dosing discontinuation		1	1.2	0	0	260	2100						
4w after DUP dosing discontinuation		1	1.2	1	2	260	2100						
8w after DUP dosing discontinuation		1	1.2	1	2	260	2100						
Initiation of DUP re-treatment			19.6	3	11	498	2150						
16w after DUP re-initiation		2	11.2	0	0	561	2250						
0w	5	4	52.2	no data	no data	19140	1480	62	F	no data	childhood	58	19
16w		1	2.8	1	2	489	889						
DUP dosing discontinuation		1	2.8	0	4	153	208						
4w after DUP dosing discontinuation		1	2.8	0	4	153	208						
8w after DUP dosing discontinuation		1	2.8	0	4	153	208						
Initiation of DUP re-treatment		2	11.2	4	16	1097	362						
16w after DUP re-initiation		2	5.2	3	3	253	322						
0w	6	3	22.4	14	18	1513	8710	48	M	no data	early childhood	64	17
16w		1	10.8	2	4	346	4930						
DUP dosing discontinuation		1	5.6	0	0	329	2780						
4w after DUP dosing discontinuation		1	5.6	0	0	329	2780						
8w after DUP dosing discontinuation		1	5.6	0	0	329	2780						
Initiation of DUP re-treatment		1	17.2	3	12	779	3010						
16w after DUP re-initiation		1	12.4	0	1	386	2850						
0w	7	3	28	15	28	1432	1590	49	M	19.9	3m	79	28
16w		3	13.5	10	9	318	802						
DUP dosing discontinuation		1	4.7	7	12	344	410						
4w after DUP dosing discontinuation		1	4.7	7	12	344	410						
8w after DUP dosing discontinuation		1	4.7	7	12	344	410						

Initiation of DUP re-treatment	3	18.2	29	28	1388	590							
16w after DUP re-initiation	1	5.6	9	9	1388	590							
Remission group													
0w	8	3	39.6	5	19	11680	27100	50	M	no data	15y	55	54
16w		1	4.2	1	2	779	11100						
DUP dosing discontinuation		0	2.4	0	0	172	5800						
4w after DUP dosing discontinuation		0	2.4	0	0	172	5800						
8w after DUP dosing discontinuation		0	2.4	0	0	240	4570						
16w after DUP dosing discontinuation		1	2.8	1	2	495	3110						
0w	9	4	46.5	14	24	5777	29300	25	M	no data	several months	70	44
16w		2	3.4	8	1	329	10300						
DUP dosing discontinuation		1	2.7	4	1	407	4070						
4w after DUP dosing discontinuation		1	2.7	4	1	407	4070						
8w after DUP dosing discontinuation		1	2.7	1	0	407	4070						
16w after DUP dosing discontinuation		1	2.7	1	0	407	4070						
0w	10	3	26.7	9	10	696	6380	38	M	26.5	early childhood	42	54
16w		2	4.1	1	4	343	3340						
DUP dosing discontinuation		1	4.7	2	1	316	2680						
4w after DUP dosing discontinuation		1	4.7	1	2	316	2680						
8w after DUP dosing discontinuation		1	4.7	2	2	326	2300						
16w after DUP dosing discontinuation		1	5.3	2	2	326	2300						
0w	11	4	28.7	9	13	3476	5580	36	M	no data	early childhood	62	21
16w		3	5.8	2	1	659	2970						
DUP dosing discontinuation		1	4	0	0	1603	4310						
4w after DUP dosing discontinuation		1	4.4	0	0	1603	4310						
8w after DUP dosing discontinuation		1	4.4	0	0	1603	4310						

16w after DUP dosing discontinuation	1	4.4	0	1	1603	4310							
0w	12	3	22	6	21	342	5040	47	M	no data	20y	65	44
16w	3	11.6	2	6	126	2390							
DUP dosing discontinuation	1	3	2	5	125	1820							
4w after DUP dosing discontinuation	1	3	2	5	125	1820							
8w after DUP dosing discontinuation	1	3	2	4	152	1400							
16w after DUP dosing discontinuation	1	3	2	4	152	1400							
0w	13	3	30.2	12	27	1487	14300	40	M	no data	early childhood	69	30
16w	1	2.5	3	5	362	7340							
DUP dosing discontinuation	1	2.6	1	5	358	4130							
4w after DUP dosing discontinuation	1	2.6	1	5	358	4130							
8w after DUP dosing discontinuation	1	2.6	1	5	358	4130							
16w after DUP dosing discontinuation	1	3.4	2	6	580	2650							
0w	14	4	49.2	5	16	1547	9480	48	F	no data	4y	68	51
16w	1	3.3	1	2	143	5030							
DUP dosing discontinuation	1	0.3	0	0	166	1770							
4w after DUP dosing discontinuation	1	0.3	0	0	166	1770							
8w after DUP dosing discontinuation	1	0.3	0	1	166	1770							
16w after DUP dosing discontinuation	1	0.9	1	2	166	1770							
0w	15	3	40.9	7	16	1190	3460	26	F	no data	6m	45	69
16w	3	33.4	2	7	831	1640							
DUP dosing discontinuation	3	11.1	2	6	327	1250							
4w after DUP dosing discontinuation	3	11.1	2	6	327	1250							
8w after DUP dosing discontinuation	3	11.1	2	6	327	1250							
16w after DUP dosing discontinuation	2	10.2	2	8	327	1250							

0w	16	4	40.4	18	16	2154	29.3	27	M	no data	after birth	69	30
16w		1	8.1	0	0	308	10.3						
DUP dosing discontinuation		1	7.9	0	1	205	8.2						
4w after DUP dosing discontinuation		1	7.9	0	1	296	6.9						
8w after DUP dosing discontinuation		3	17.9	2	3	270	5.6						
16w after DUP dosing discontinuation		2	14.7	0	2	270	5.6						
0w	17	4	32.1	no data	no data	1954	11300	53	M	no data	35y	59	28
16w		2	9	no data	no data	614	5340						
DUP dosing discontinuation		1	4.3	5	3	457	1850						
4w after DUP dosing discontinuation		1	4.3	5	3	457	1850						
8w after DUP dosing discontinuation		1	4.3	5	3	457	1850						
16w after DUP dosing discontinuation		0	1.8	5	3	457	1850						
0w	18	3	17.4	5	7	755	1350	24	M	no data	12y	40	72
16w		1	2	1	1	315	606						
DUP dosing discontinuation		0	0	1	1	317	305						
4w after DUP dosing discontinuation		0	0	1	1	317	305						
8w after DUP dosing discontinuation		0	0	1	1	317	305						
16w after DUP dosing discontinuation		0	0	1	1	317	305						
0w	19	3	18.2	13	21	2217	9750	44	M	23.3	3y	52	19
16w		2	2.6	4	10	738	6680						
DUP dosing discontinuation		2	2.6	2	3	738	6680						
4w after DUP dosing discontinuation		2	2.6	1	4	581	2700						
8w after DUP dosing discontinuation		2	2.6	1	4	581	2700						
16w after DUP dosing discontinuation		2	2.8	3	10	581	2700						
0w	20	3	15.2	15	10	6486	1320	40	F	25.9	early childhood	64	19

16w		2	12.8	4	2	653	394							
DUP dosing discontinuation		2	12.8	1	1	653	394							
4w after DUP dosing discontinuation		2	13.2	2	0	610	94.9							
8w after DUP dosing discontinuation		2	13.2	2	0	610	94.9							
16w after DUP dosing discontinuation		2	4.8	2	0	610	94.9							
0w	21	4	59.4	9	14	39650	25500	49	F	no data	after birth	57		21
16w		2	11.6	1	2	368	4870							
DUP dosing discontinuation		1	6.1	1	4	391	1140							
4w after DUP dosing discontinuation		1	6.1	1	5	391	1140							
8w after DUP dosing discontinuation		1	6.1	1	1	279	932							
16w after DUP dosing discontinuation		1	6.1	1	1	279	932							
0w	22	4	40.2	4	0	809	4430	18	F	20.7	4m	24		52
16w		2	7.5	1	2	148	2970							
DUP dosing discontinuation		1	2.5	0	0	148	2970							
4w after DUP dosing discontinuation		1	2.5	0	0	148	2970							
8w after DUP dosing discontinuation		1	2.5	0	0	148	2970							
16w after DUP dosing discontinuation		1	2.5	1	1	258	1500							

IGA: Investigator's Global Assessment; EASI: Eczema Area and Severity Index; DLQI: Dermatology Life Quality Index; POEM: Patient Oriented Eczema Measure; TARC: thymus and activation-regulated chemokine; AD: atopic dermatitis; DUP: dupilumab; w: weeks; m: months; y: years; M: male; F: female.